The Commission presents a proposal to enhance the control of drug precursors, the chemical substances that are used by both legitimate industries and in the production of illicit drugs. As Europe’s drug market evolves, the proposal strengthens authorities to respond to emerging drugs and production processes.
This initiative aims to simplify EU legislation on medical devices and diagnostics to enhance competitiveness, foster innovation and ensure proportionate, cost-effective safety requirements while maintaining high levels of patient protection and public health.
The next Consumer Agenda 2025-2030, scheduled for adoption on 19 November 2025, will include a new action plan on consumers in the single market ensuring a balanced approach that protects consumers without overburdening companies with red tape.
This opinion explores the potential of the bioeconomy and how policies can ensure its long-term competitiveness and investment security, while safeguarding nature. It will present civil society's views on further goals which include increasing resource-efficient and circular use of biological resources, securing a sustainable supply of biomass, both within the EU and from international sources, and strengthening the EU’s position in the rapidly expanding global bioeconomy.
